Transplantation as disease modifying therapy in the era of gene therapy medicinal products – health policy considerations
Rattachement africain : nl, ca. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: New gene therapy medicinal products [GTMP] are being considered as alternatives to liver transplant [LTx] for some patients with inherited metabolic diseases [IMDs] but pose unique challenges for health policy makers. METHODS: Published data on LTx and GTMP in human patients with urea cycle defects [UCD], glycogen storage disease type 1a [GSD1a], methylmalonic aciduria [MMA] and propionic aciduria [PA] were reviewed for efficacy, safety, data quality and health policy considerations. RESULTS: LTx can reduce [MMA, PA] or eliminate [UCD, GSD1a] metabolic decompensation and improve quality of life. Risk of death peaks in the first year but long-term survival post LTx is similar to medical management. Initial data for GTMP show reduction in metabolic decompensation [MMA, PA, UCD] with more modest impacts in GSD1a. Long-term safety and efficacy data [available for LTx] may not be available at the time of market authorization for GTMP. Age is one health policy challenge as clinical trials for GTMP may target one age group but other age groups may request consideration for treatment. Quality concerns regarding data analysis exist for both modalities. Cost effectiveness of LTx is likely to be significantly more favorable than for GTMP. Access limitations are severe for both treatments, with high opportunity costs [price for GTMP, organ availability for LTx] mandating the need to engage the public as stakeholders in addition to patients, families, manufacturers and clinicians. CONCLUSIONS: LTx remains an effective treatment choice in the era of GTMP given the significant health policy challenges associated with these novel therapies.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Transplantation as disease modifying therapy in the era of gene therapy medicinal products – health policy considerations
- Date Crossref
- 13/08/2026
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Erasmus MC Department of Gastroenterology and Hepatology pays non établi dans la noticeÉtablissement de santé
-
Erasmus University Rotterdam pays non établi dans la noticeUniversité ou école supérieure
-
University of British Columbia Adult Metabolic Diseases Clinic pays non établi dans la noticeUniversité ou école supérieure
-
Amsterdam Neuroscience pays non établi dans la noticeStructure de recherche
-
Amsterdam Gastroenterology Endocrinology Metabolism pays non établi dans la noticeÉtablissement de santé
-
University of Amsterdam Department of Endocrinology and Metabolism pays non établi dans la noticeUniversité ou école supérieure
-
University Medical Center Rotterdam Department of Internal Medicine pays non établi dans la noticeUniversité ou école supérieure
Department of Gastroenterology and Hepatology — Erasmus MC, Erasmus University Rotterdam et Adult Metabolic Diseases Clinic — University of British Columbia, avec 4 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.